OncLive TV

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax for mantle cell lymphoma.

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the next steps in the kidney cancer paradigm.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses regional nodal irradiation for the treatment of patients with breast cancer.

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the interest in using PARP inhibitors in patients with prostate cancer.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares the 2 available BTK inhibitors for patients with mantle cell lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses an investigational cellular therapy in colorectal cancer.

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy in non-clear cell renal cancer.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the use of immunotherapy in the treatment of pediatric patients with cancer.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the rarity and characteristics of uterine sarcomas.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the PACIFIC trial results on the treatment landscape of stage III non–small cell lung cancer.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunogenicity in triple-negative breast cancer (TNBC).

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.